Literature DB >> 30093158

Evolution of survivorship in lymphoma, myeloma and leukemia: Metamorphosis of the field into long term follow-up care.

Moussab Damlaj1, Riad El Fakih2, Shahrukh K Hashmi3.   

Abstract

Recent advancements in cancer care, coupled with early detection and an aging population have resulted in significant growth of cancer survivors. Long term follow up of such survivors is essential given the heightened risk for development of late effects such as secondary neoplasms, cardiovascular disease or psychosocial dysfunction among others. As more patients with hematologic malignancies are cured or managed over protracted periods of time, awareness of such issues is paramount for the practicing clinicians for optimal patient management. In this review, we describe the genesis of the field of cancer survivorship, and then it's gentle metamorphosis into multiple sub-fields currently by presenting literature relevant to late effects commonly seen in Hodgkin lymphoma, non-Hodgkin lymphoma, chronic leukemia and multiple myeloma. We will discuss the strengths and pitfalls of the existing models of survivorship care in hematologic malignancies and conclude with expert perspective on how to move the field forward.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Late effects; Survivorship; Survivorship care plan

Mesh:

Year:  2018        PMID: 30093158     DOI: 10.1016/j.blre.2018.07.003

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  12 in total

1.  Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells.

Authors:  Ana Cordeiro; Evandro D Bezerra; Alexandre V Hirayama; Joshua A Hill; Qian V Wu; Jenna Voutsinas; Mohamed L Sorror; Cameron J Turtle; David G Maloney; Merav Bar
Journal:  Biol Blood Marrow Transplant       Date:  2019-08-13       Impact factor: 5.742

2.  The impact of prior malignancies on the development of second malignancies and survival in follicular lymphoma: A population-based study.

Authors:  Manette A W Dinnessen; Otto Visser; Sanne H Tonino; Marjolein W M van der Poel; Nicole M A Blijlevens; Marie José Kersten; Pieternella J Lugtenburg; Avinash G Dinmohamed
Journal:  EJHaem       Date:  2020-10-08

3.  The application value of informatization-based extended nursing care on discharged children with leukemia.

Authors:  Min Li; Yulei Jia; Lili Zhang
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

4.  Evidence-Based Follow-up for Adults With Cancer.

Authors:  Ulrich Dührsen; Karl-Matthias Deppermann; Christian Pox; Axel Holstege
Journal:  Dtsch Arztebl Int       Date:  2019-10-04       Impact factor: 5.594

5.  Sublethal whole-body irradiation causes progressive premature frailty in mice.

Authors:  Edward Fielder; Melanie Weigand; Julien Agneessens; Brigid Griffin; Craig Parker; Satomi Miwa; Thomas von Zglinicki
Journal:  Mech Ageing Dev       Date:  2019-04-04       Impact factor: 5.432

Review 6.  Senolytics and senostatics as adjuvant tumour therapy.

Authors:  Susan Short; Edward Fielder; Satomi Miwa; Thomas von Zglinicki
Journal:  EBioMedicine       Date:  2019-02-06       Impact factor: 8.143

7.  Relaxation and exercise in lymphoma survivors (REIL study): a randomised clinical trial protocol.

Authors:  Suchita Hathiramani; Ruth Pettengell; Hannah Moir; Ahmed Younis
Journal:  BMC Sports Sci Med Rehabil       Date:  2019-08-16

8.  Lymphoma survivors' experience of participation in a home-based intervention post-chemotherapy.

Authors:  Suchita Hathiramani; R Pettengell; H Moir; A Younis
Journal:  Qual Life Res       Date:  2019-07-04       Impact factor: 4.147

9.  Sustained degradation of quality of life in a subgroup of lymphoma survivors: a two-year prospective survey.

Authors:  Gisèle Compaci; Cécile Conte; Lucie Oberic; Loïc Ysebaert; Guy Laurent; Fabien Despas
Journal:  BMC Cancer       Date:  2019-12-03       Impact factor: 4.430

10.  Relaxation versus exercise for improved quality of life in lymphoma survivors-a randomised controlled trial.

Authors:  Suchita Hathiramani; R Pettengell; H Moir; A Younis
Journal:  J Cancer Surviv       Date:  2020-09-28       Impact factor: 4.442

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.